SLC5A2 and heart failure: The recently published EMPEROR-Preserved trial using Empagliflozin (Empa), a sodium glucose cotransporter-2 inhibitor (SGLT2i), reported positive effects on the combined clinical endpoint of cardiovascular death or hospitalization for heart failure compared to placebo in patients with HFpEF [14].